Published in J Virol on December 01, 2002
VP2 cleavage and the leucine ring at the base of the fivefold cylinder control pH-dependent externalization of both the VP1 N terminus and the genome of minute virus of mice. J Virol (2006) 1.41
Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J Virol (2008) 1.30
The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry. J Virol (2005) 1.15
Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J (2007) 1.06
Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus. J Virol (2010) 1.04
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J Virol (2010) 1.04
Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J (2009) 1.01
Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. PLoS Pathog (2008) 0.99
Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus. J Virol (2009) 0.97
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains. J Virol (2004) 0.96
Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol (2006) 0.93
Parvoviruses cause nuclear envelope breakdown by activating key enzymes of mitosis. PLoS Pathog (2013) 0.90
Pathways of cell infection by parvoviruses and adeno-associated viruses. J Virol (2004) 0.89
Replication of the rotavirus genome requires an active ubiquitin-proteasome system. J Virol (2011) 0.88
The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J Virol (2010) 0.83
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
Classic nuclear localization signals and a novel nuclear localization motif are required for nuclear transport of porcine parvovirus capsid proteins. J Virol (2014) 0.80
Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells. Virology (2008) 0.77
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A (1988) 10.77
Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem (1996) 10.70
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Virus entry into animal cells. Adv Virus Res (1989) 7.78
Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol (1998) 7.27
Membrane fusion proteins of enveloped animal viruses. Q Rev Biophys (1983) 6.31
Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell (1991) 6.30
The autonomously replicating parvoviruses of vertebrates. Adv Virus Res (1987) 5.80
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. J Cell Biol (1989) 4.88
THREE DEGREES OF GUANYLIC ACID--INOSINIC ACID PYROPHOSPHORYLASE DEFICIENCY IN MOUSE FIBROBLASTS. Nature (1964) 4.67
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell (2001) 3.97
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. Eur J Biochem (1979) 3.66
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest (2000) 3.57
Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J Virol (1983) 3.46
Sequence homology between the structural polypeptides of minute virus of mice. J Mol Biol (1977) 3.37
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol (1998) 3.21
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump. J Cell Biol (1995) 3.03
Antigen processing by the proteasome. Nat Rev Mol Cell Biol (2001) 2.93
Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection. J Virol (1998) 2.93
Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol (2002) 2.77
Mechanisms of viral transport in the cytoplasm. Trends Microbiol (2000) 2.63
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol (2001) 2.56
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol (2000) 2.08
Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol (2001) 2.08
Mechanisms of enveloped virus entry into cells. Mol Biol Med (1990) 1.87
Host cell dependence of viral morphology. Proc Natl Acad Sci U S A (1998) 1.78
The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny single-stranded DNA but is required for infectivity. J Virol (1993) 1.67
Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J Biol Chem (1997) 1.61
Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking. J Virol (2000) 1.61
How do animal DNA viruses get to the nucleus? Annu Rev Microbiol (1998) 1.59
Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell (1999) 1.58
Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J Virol (1981) 1.57
The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J Virol (2002) 1.52
Genome organization of the densovirus from Bombyx mori (BmDNV-1) and enzyme activity of its capsid. J Gen Virol (2001) 1.51
The two transcription units of the autonomous parvovirus minute virus of mice are transcribed in a temporal order. J Virol (1988) 1.49
Mechanisms of enveloped virus entry into animal cells. Adv Drug Deliv Rev (1998) 1.47
The parvovirus MVM: a comparison of heavy and light particle infectivity and their density conversion in vitro. Virology (1976) 1.43
The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol (2002) 1.42
Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport. J Virol (2000) 1.34
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A (1996) 1.29
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest (2000) 1.27
Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. J Gen Virol (1997) 1.25
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
Infectious entry pathway for canine parvovirus. Virology (1992) 1.19
The NS2 protein generated by the parvovirus minute virus of mice is degraded by the proteasome in a manner independent of ubiquitin chain elongation or activation. Virology (2001) 1.17
Characterization of a nuclear localization signal of canine parvovirus capsid proteins. Eur J Biochem (1997) 1.14
Role of recycling endosomes and lysosomes in dynein-dependent entry of canine parvovirus. J Virol (2002) 1.14
Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, blocks lysosomal cholesterol trafficking in macrophages. J Biol Chem (1993) 1.11
Phosphorylation status of the parvovirus minute virus of mice particle: mapping and biological relevance of the major phosphorylation sites. J Virol (2000) 1.11
Microtubules are involved in bafilomycin A1-induced tubulation and Rab5-dependent vacuolation of early endosomes. Eur J Cell Biol (1997) 1.11
Polarity of human parainfluenza virus type 3 infection in polarized human lung epithelial A549 cells: role of microfilament and microtubule. J Virol (2001) 1.09
Assaying for structural variation in the parvovirus capsid and its role in infection. Virology (1998) 1.08
The trypsin-sensitive RVER domain in the capsid proteins of minute virus of mice is required for efficient cell binding and viral infection but not for proteolytic processing in vivo. Virology (1992) 1.05
Intracellular route of canine parvovirus entry. J Virol (1998) 1.05
Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells. J Biol Chem (2002) 0.95
Direct evidence for nuclear and cytoplasmic colocalization of proteasomes (multiprotease complexes) in liver. J Cell Physiol (1989) 0.93
Binding of bovine parvovirus to erythrocyte membrane sialylglycoproteins. J Gen Virol (1998) 0.93
The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem (1996) 0.92
Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection. Cell Host Microbe (2011) 1.26
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology (2004) 1.15
A novel supervised trajectory segmentation algorithm identifies distinct types of human adenovirus motion in host cells. J Struct Biol (2007) 1.15
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion (2012) 1.06
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol (2011) 1.00
Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol (2008) 1.00
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2009) 0.97
A stochastic model for microtubule motors describes the in vivo cytoplasmic transport of human adenovirus. PLoS Comput Biol (2009) 0.95
The dynactin complex enhances the speed of microtubule-dependent motions of adenovirus both towards and away from the nucleus. Viruses (2011) 0.94
Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals (2003) 0.92
Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology (2005) 0.92
Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol (2013) 0.91
Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model. J Virol (2012) 0.89
Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol (2003) 0.88
Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis (2010) 0.87
Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion (2004) 0.86
Vimentin Intermediate Filaments Template Microtubule Networks to Enhance Persistence in Cell Polarity and Directed Migration. Cell Syst (2016) 0.84
Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion (2007) 0.84
The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J Virol (2010) 0.83
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2011) 0.79
Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol (2005) 0.78
Delivery of membrane impermeable cargo into CHO cells by peptide nanoparticles targeted by a protein corona. Biomaterials (2012) 0.78
Redox rescues virus from ER trap. Nat Cell Biol (2008) 0.78
Impaired genome encapsidation restricts the in vitro propagation of human parvovirus B19. J Virol Methods (2013) 0.77
Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation. Biologicals (2004) 0.77